Dr. Imran Zoberi, M.D.
Claim this profileWashington University School of Medicine
Studies Breast Cancer
Studies Thyroid Cancer
8 reported clinical trials
13 drugs studied
Area of expertise
1Breast Cancer
Stage I
ER positive
PR positive
2Thyroid Cancer
Stage I
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Imran Zoberi, M.D. is currently running
Ultra-Hypofractionated vs. Hypofractionated Radiation
for Breast Cancer
In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breast radiation therapy has evolved over time, as novel schedules have been compared to the current standard of care. Hypofractionated radiation therapy (266 cGy per fraction x 15-16 fractions over 3 weeks) has been shown to result in equivalent oncologic outcomes, as well as equivalent acute and late toxicity, when compared to standard fractionation (200 cGy per fraction x 25 fractions over 5 weeks). Subsequently, hypofractionated breast radiation has become the current standard of care. More recently, ultra-hypofractionated breast radiation (520 cGy per fraction x 5 fractions over 1 week) was shown in a randomized trial to be non-inferior to hypofractionated radiation when treating the breast after lumpectomy. However, the efficacy and toxicity of using ultra-hypofractionated radiation therapy when also treating the regional nodes has not been reported. This is important, as there is greater radiation exposure to several normal tissues, such as the arm/shoulder, brachial plexus, normal lymphatics, heart, and lung, when treating the regional nodes. In this randomized study, the investigators aim to compare the tolerability and efficacy of ultra-hypofractionated breast/chest wall and regional nodal radiation (SWIFT RT) against hypofractionated radiation (RT). The investigators will evaluate acute and late toxicity, oncologic outcomes (including local recurrence, regional recurrence, distant metastasis, and overall survival), cosmesis, and patient-reported quality of life. The investigators will collect blood samples for correlative studies of biomarkers of fibrosis and cardiac toxicity.
Recruiting1 award Phase 29 criteria
Chemotherapy and Radiation
for Cutaneous Angiosarcoma
Angiosarcoma is a rare and aggressive form of soft tissue sarcoma. Prior work demonstrates very poor outcomes, with most patients developing metastatic disease and less than 50% surviving greater than 5 years. In other soft tissue sarcomas, the use of radiotherapy and/or chemotherapy have improved progression-free survival in patients undergoing limited, organ-sparing surgeries. Taxane chemotherapy has shown efficacy in patients with metastatic angiosarcoma, but this has not been tested in patients with localized disease. This study examines the efficacy of induction paclitaxel followed by concurrent chemoradiation therapy with paclitaxel prior to curative surgical resection.
Recruiting1 award Phase 1 & 27 criteria
More about Imran Zoberi, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Imran Zoberi, M.D. has experience with
- Radiation Therapy
- Three Fraction APBI
- Accelerated Partial Breast Irradiation
- Photon
- Proton
- Circulating Tumor DNA (ctDNA)
Breakdown of trials Imran Zoberi, M.D. has run
Breast Cancer
Thyroid Cancer
Skin Cancer
Lobular Carcinoma in Situ
Ductal Carcinoma In Situ
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Imran Zoberi, M.D. specialize in?
Imran Zoberi, M.D. focuses on Breast Cancer and Thyroid Cancer. In particular, much of their work with Breast Cancer has involved Stage I patients, or patients who are ER positive.
Is Imran Zoberi, M.D. currently recruiting for clinical trials?
Yes, Imran Zoberi, M.D. is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Imran Zoberi, M.D. has studied deeply?
Yes, Imran Zoberi, M.D. has studied treatments such as Radiation therapy, Three Fraction APBI, Accelerated Partial Breast Irradiation.
What is the best way to schedule an appointment with Imran Zoberi, M.D.?
Apply for one of the trials that Imran Zoberi, M.D. is conducting.
What is the office address of Imran Zoberi, M.D.?
The office of Imran Zoberi, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.